Edicotinib is under clinical development by Provention Bio and currently in the Phase II in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.

According to GlobalData, the latest event to affect Edicotinib’s likelihood of approval (LoA) and phase transition for Refractory Acute Myeloid Leukemia took place on 18 Nov 2020, which decreased the likelihood that the drug progresses to the next phase in its clinical pathway and decreased the likelihood of final approval for this indication.

In addition, the same event on 18 Nov 2020 decreased Edicotinib’s LoA and PTSR for Relapsed Acute Myeloid Leukemia.

GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their Edicotinib Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.

Edicotinib overview

Edicotinib (PRV-6527, JNJ-40346527) is under development for the treatment of relapsed and refractory acute myeloid leukemia and alzheimer's disease. The drug candidate is administered orally. It is a small molecule inhibitor of colony-stimulating factor-1 receptor (CSF1R; FMS). It was also under development for the treatment of rheumatoid arthritis, Crohn's disease and relapsed or refractory Hodgkin lymphoma.

Provention Bio overview

Provention Bio (Provention), is a clinical-stage biopharmaceutical company. It develops novel therapeutics for intercepting and preventing immune-mediated diseases. The company’s pipeline product portfolio includes PRV-031 teplizumab for the treatment of type one diabetes (T1D); PRV-015 is an anti-IL-15 monoclonal antibody for gluten-free diet non-responsive celiac disease (NRCD). It also develops PRV-3279 for preventing immunogenicity and SLE; PRV-101 is a polyvalent coxsackievirus B (CVB) vaccine developed for treating type one diabetes (T1D). Provention has licensing and co-development agreement with pharmaceutical and biotherapeutic industries includes Vactech Oy, Amgen Inc and MacroGenics Inc. Provention is headqutered in Red Bank, New Jersey, the US.

Quick View Edicotinib LOA Data

Report Segments
  • Innovator
Drug Name
  • Edicotinib
Administration Pathway
  • Oral
Therapeutic Areas
  • Central Nervous System
  • Gastrointestinal
  • Immunology
  • Oncology
Key Developers
Highest Development Stage
  • Phase II

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.